arrow
L

Laura G.M. Daenen

University Medical Center Utrecht
H指数:15
被引数:1,638

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Peri-transplant ruxolitinib in myelofibrosis patients undergoing αβTCR and CD19-depleted stem cell transplantation

移植前后使用鲁索利替尼治疗接受αβTCR和CD19耗竭干细胞移植的骨髓纤维化患者

2026-10-060
PRE
Eltrombopag Added to Standard Immunosuppressive Treatment as Front-Line Therapy for Severe Aplastic Anemia: Long-Term Outcomes of the Phase-3 Randomized Superiority EBMT-SAAWP RACE Study

eltrombopag添加到标准免疫抑制治疗中作为一线疗法治疗重症再生障碍性贫血:EBMT-SAAWP RACE研究3期随机优越性研究的长期结果

2026-07-280
OAAI
Interim analysis of a multicenter study on patient-guided dose reduction of tyrosine kinase inhibitors in chronic myeloid leukemia: the RODEO study

Lokhorst, D.N.; Smit, Y.; Bemt, B.J.V.D.; Hermens, R.P.; Nijziel, M.R.; Jie, A.K.-S.; Daenen, L.G.; Klein, S.K.; Posthuma, E.F.; Westerweel, P.E.; 等. 多中心研究中期分析:慢性髓性白血病患者指导的酪氨酸激酶抑制剂剂量减少——RODEO研究. Haematologica 2026, 111, 918–926. [Google Scholar] [CrossRef]

2026-03-012
PRE
αβT/CD19-depleted Allogeneic Stem Cell Transplantation in Adults with Inborn Errors of Immunity

αβT/CD19耗竭的异基因造血干细胞移植在免疫先天性缺陷成人中的应用

2026-02-030
OAAI
Improved GVHD-free and relapse-free survival after ex vivo αβTCR and CD19 depleted allogeneic HSCT compared to T cell replete HSCT

与含T细胞的异基因HSCT相比,经体外αβTCR和CD19清除的异基因HSCT改善了无GVHD和无复发生存率。

2025-03-150
PRE
The use of MSCs in steroid-refractory acute GvHD in Europe: a survey from the EBMT cellular therapy & immunobiology working party

欧洲间充质干细胞在糖皮质激素难治性急性移植物抗宿主病中的应用:欧洲血液和骨髓移植组细胞治疗与免疫生物学工作组调查

2025-02-200
PRE
Regulation of E2F1 by the von Hippel-Lindau tumour suppressor protein predicts survival in renal cell cancer patients

von hippel-lindau肿瘤抑制蛋白对E2F1的调节可预测肾细胞癌患者的生存

2013-08-0618
OAAI